scholarly journals Potential market size and impact of hepatitis C treatment in low‐ and middle‐income countries

2016 ◽  
Vol 23 (7) ◽  
pp. 522-534 ◽  
Author(s):  
M. E. Woode ◽  
M. Abu‐Zaineh ◽  
J. Perriëns ◽  
F. Renaud ◽  
S. Wiktor ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Market Size ◽  
Hepatitis C Treatment ◽  
Middle Income ◽  
Middle Income Countries ◽  
Potential Market ◽  
Low And Middle Income

scholarly journals Barriers to access to hepatitis C treatment

2016 ◽  
Vol 10 (04) ◽  
pp. 308-316 ◽  
Author(s):  
Hava Yilmaz ◽  
Esmeray Mutlu Yilmaz ◽  
Hakan Leblebicioglu
Keyword(s):  
Hepatitis C ◽  
Diagnostic Testing ◽  
Antiviral Agents ◽  
Drug Market ◽  
Developed Countries ◽  
Hcv Infection ◽  
Hepatitis C Treatment ◽  
Middle Income ◽  
Middle Income Countries ◽  
Low And Middle Income

Hepatitis C virus (HCV) is a major cause of chronic liver disease worldwide. Only 1%–30% of patients in need of treatment may get it. In recent years, the availability of direct-acting antiviral agents (DAA) has been an important advancement in treating HCV infection. However, due to cost, it is not possible to receive these drugs in many countries where infection is endemic. In these low- and middle-income countries, the main barriers to controlling HCV infection are lack of knowledge about the infection, constraints on diagnostic testing and treatment, and lack of experts. Both national and international support are essential to overcoming these barriers. In low- and middle-income countries, interferon and ribavirin-based therapies still are the first choices due to their availability and to government payment support. In addition, in developed countries, efforts to provide lower-cost DAA drugs continue. Pharmaceutical companies continue to research manufacture of bio-equivalent drugs to reduce treatment costs. Considering the fake drug market, all developments need to be monitored closely by the institutions involved. This review focuses on barriers to hepatitis C treatment and ways to overcome those barriers.

scholarly journals Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme

2020 ◽  
Author(s):  
Salamat Ali ◽  
Tofeeq Ur-Rehman ◽  
Mashhood Ali ◽  
Sayeed Haque ◽  
Faisal Rasheed ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Hepatitis C ◽  
Average Cost ◽  
Cost Effectiveness Ratio ◽  
Hepatitis C Treatment ◽  
Middle Income ◽  
Middle Income Countries ◽  
Assistance Programme ◽  
Patient Assistance ◽  
Low And Middle Income

AbstractBackground Modern antiviral treatments have high cure rates against the hepatitis C virus however, the high cost associated with branded medicines and diagnostic tests, have resulted in poor access for many low-income patients residing in low-and-middle-income countries. Objective This study aimed to evaluate the role of a patient assistance programme and generic medicines in improving access to treatment of low-income hepatitis C patients in a low-and-middle-income country. Setting A major teaching public hospital in Islamabad, Pakistan. Methods Hepatitis C patients who presented and enrolled for the patient assistance programme during 12 months (1st July 2015 and 30th June 2016) were included. Demography, prescription characteristics, the total costs of Hepatitis C treatment, medicine cost supported by the programme, out-of-pocket cost borne by the patient and average cost effectiveness ratio per sustained virologic response were calculated and compared for different generic and branded regimens. Main outcome measure cost contribution of patient assistance programme. Results A total of 349 patients initiated the treatment through the programme and of those 334 (95.7%) completed the prescribed treatment. There were 294 (88.02%) patients who achieved sustained virologic response. Patient assistance programme contributed medicines cost averaging 60.28–86.26% of the total cost of treatment ($1634.6) per patient. The mean (SE) cost per patient for generic option (Sofosbuvir/Ribavirin) was the lowest [$658.36 (22.3) per patient, average cost effectiveness ratio = $720.1/SVR] than branded option (Sovaldi/Ribavirin) [$2218.66 (37.6) per patient, average cost effectiveness ratio = $2361.8/SVR] of the three available treatment regimens. From patients’ perspectives, the mean (SE) out-of-pocket cost was $296.9 (6.7) which primarily included diagnostic cost (69.9%) of the total cost. Conclusions Patient assistance programme, combined with generic brands of newer hepatitis C treatment offered a significant reduction in cost and widens access to hepatitis C treatment in low-and middle-income countries. However, substantial out-of-pocket costs of the treatment presents an important barrier for service access. There is a scope to widen such financial assistance programme to offer other costs attributed to patients, specifically for diagnosis, to widen service use in low-and-middle-income countries.

LBP-37-Evaluation of Hepatitis C Virus Rapid Diagnostic Test in HCV mono- and HCV/HIV co-infected patients from Low and Middle Income Countries

2019 ◽  
Vol 70 (1) ◽  
pp. e159-e160
Author(s):  
Beatrice Vetter ◽  
Elena Ivanova Reipold ◽  
Rosemary Audu ◽  
Maia Alkhazashvili ◽  
Anja De Weggheleire ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Diagnostic Test ◽  
Rapid Diagnostic Test ◽  
Middle Income ◽  
Middle Income Countries ◽  
Low And Middle Income

Access to hepatitis C treatment for people who inject drugs in low and middle income settings: Evidence from 5 countries in Eastern Europe and Asia

2015 ◽  
Vol 26 (11) ◽  
pp. 1081-1087 ◽  
Author(s):  
Niklas Luhmann ◽  
Julie Champagnat ◽  
Sergey Golovin ◽  
Ludmila Maistat ◽  
Edo Agustian ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Eastern Europe ◽  
People Who Inject Drugs ◽  
Hepatitis C Treatment ◽  
Middle Income ◽  
Low And Middle Income
Sign in / Sign up

Export Citation Format

Share Document